Aurealis Therapeutics
Multi-target cell and gene therapy for chronic wounds and cancer. Lead product AUP-16 is a genetically engineered, non-pathogenic Lactococcus cremoris delivering four therapeutic proteins directly into the wound bed, developed for diabetic foot ulcers, venous leg ulcers and pressure ulcers; the DIAMEND Phase 2 trial in diabetic foot ulcers has completed treatment with positive blinded-evaluator efficacy results, and Greater China rights are licensed to Xbiome. Group is Swiss-Finnish: Aurealis Therapeutics AG with the operating and R&D subsidiary Aurealis Oy in Kuopio (y 2330296-8, founded 2010).
The row
- Stage
- Pre-revenue — No sales yet
- Location
- Kuopio
- Founded
- 2010
- Business ID
- 2330296-8 · Finnish trade register
- Funding
- $10M (Series A, 2023); ~$40M total (approx. 2024, no official announcement)
Links
Where this sits on the map
Aurealis Therapeutics is one of 33 companies in Therapeutics & Diagnostics. The others:
How this row was decided
Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗